Drug Trial Radar · NCT01191723
QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo
Last checked: Nov 19, 2026Latest source record: Jan 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Aug 2010
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
- First posted
- Aug 31, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Compare the acute effect on the QT interval of MAP0004 (Dihydroergotamine Mesylate delivered by Oral Inhalation) with Moxifloxacin and Placebo.
Conditions
- Healthy
Interventions
MAP0004Drug
3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
Inhaler PlaceboDrug
Placebo for Inhaler administered in Treatments A and C
MoxifloxacinDrug
400mg encapsulated tablet administered in Treatment A as per protocol
Placebo CapsuleDrug
Placebo for Moxifloxacin administered in Treatment B and Treatment C
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in QTcI for MAP0004 3.0mg and Placebo at 30 MinutesTime frame: baseline and 30 minutes
- Change From Baseline in QTcI for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 HoursTime frame: baseline and 2 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cetero Research
Fargo, North Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.